201 related articles for article (PubMed ID: 27423937)
1. Selective GPR55 antagonism reduces chemoresistance in cancer cells.
Singh NS; Bernier M; Wainer IW
Pharmacol Res; 2016 Sep; 111():757-766. PubMed ID: 27423937
[TBL] [Abstract][Full Text] [Related]
2. GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts.
Bernier M; Catazaro J; Singh NS; Wnorowski A; Boguszewska-Czubara A; Jozwiak K; Powers R; Wainer IW
Int J Cancer; 2017 Nov; 141(10):2131-2142. PubMed ID: 28741686
[TBL] [Abstract][Full Text] [Related]
3. Concurrent activation of β
Wnorowski A; Such J; Paul RK; Wersto RP; Indig FE; Jozwiak K; Bernier M; Wainer IW
Cell Signal; 2017 Aug; 36():176-188. PubMed ID: 28495590
[TBL] [Abstract][Full Text] [Related]
4. Deprogramming metabolism in pancreatic cancer with a bi-functional GPR55 inhibitor and biased β
Wnorowski A; Dudzik D; Bernier M; Wójcik J; Keijzers G; Diaz-Ruiz A; Mazur K; Zhang Y; Han H; Scheibye-Knudsen M; Jozwiak K; Barbas C; Wainer IW
Sci Rep; 2022 Mar; 12(1):3618. PubMed ID: 35256673
[TBL] [Abstract][Full Text] [Related]
5. (R,R')-4'-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility.
Paul RK; Wnorowski A; Gonzalez-Mariscal I; Nayak SK; Pajak K; Moaddel R; Indig FE; Bernier M; Wainer IW
Biochem Pharmacol; 2014 Feb; 87(4):547-61. PubMed ID: 24355564
[TBL] [Abstract][Full Text] [Related]
6. Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.
Zhao Y; Shen S; Guo J; Chen H; Greenblatt DY; Kleeff J; Liao Q; Chen G; Friess H; Leung PS
J Surg Res; 2006 Dec; 136(2):325-35. PubMed ID: 17054996
[TBL] [Abstract][Full Text] [Related]
7. Activation of β2-adrenergic receptor by (R,R')-4'-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells.
Wnorowski A; Sadowska M; Paul RK; Singh NS; Boguszewska-Czubara A; Jimenez L; Abdelmohsen K; Toll L; Jozwiak K; Bernier M; Wainer IW
Cell Signal; 2015 May; 27(5):997-1007. PubMed ID: 25703025
[TBL] [Abstract][Full Text] [Related]
8. Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1α and MDR1.
Hassan S; Peluso J; Chalhoub S; Idoux Gillet Y; Benkirane-Jessel N; Rochel N; Fuhrmann G; Ubeaud-Sequier G
PLoS One; 2020; 15(10):e0240676. PubMed ID: 33052979
[TBL] [Abstract][Full Text] [Related]
9. Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells.
Kim DJ; Park YS; Kang MG; You YM; Jung Y; Koo H; Kim JA; Kim MJ; Hong SM; Lee KB; Jang JJ; Park KC; Yeom YI
Exp Cell Res; 2015 Aug; 336(1):119-29. PubMed ID: 26112218
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Yokoi K; Fidler IJ
Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
[TBL] [Abstract][Full Text] [Related]
11. CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells.
Kato H; Seto K; Kobayashi N; Yoshinaga K; Meyer T; Takei M
Life Sci; 2011 Oct; 89(17-18):603-8. PubMed ID: 21839751
[TBL] [Abstract][Full Text] [Related]
12. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
[TBL] [Abstract][Full Text] [Related]
13. A multiple-targets alkaloid nuciferine overcomes paclitaxel-induced drug resistance in vitro and in vivo.
Liu RM; Xu P; Chen Q; Feng SL; Xie Y
Phytomedicine; 2020 Dec; 79():153342. PubMed ID: 32992085
[TBL] [Abstract][Full Text] [Related]
14. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
15. CBP-dependent Wnt/β-catenin signaling is crucial in regulation of MDR1 transcription.
Xia Z; Guo M; Liu H; Jiang L; Li Q; Peng J; Li JD; Shan B; Feng P; Ma H
Curr Cancer Drug Targets; 2015; 15(6):519-32. PubMed ID: 25968898
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract][Full Text] [Related]
17. The Chemosensitizing Role of Metformin in Anti-Cancer Therapy.
Tang Z; Tang N; Jiang S; Bai Y; Guan C; Zhang W; Fan S; Huang Y; Lin H; Ying Y
Anticancer Agents Med Chem; 2021; 21(8):949-962. PubMed ID: 32951587
[TBL] [Abstract][Full Text] [Related]
18. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
Ricciardi S; Mey V; Nannizzi S; Pasqualetti G; Crea F; Del Tacca M; Danesi R
Chemotherapy; 2010; 56(4):303-12. PubMed ID: 20714148
[TBL] [Abstract][Full Text] [Related]
19. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
Singh S; Srivastava SK; Bhardwaj A; Owen LB; Singh AP
Br J Cancer; 2010 Nov; 103(11):1671-9. PubMed ID: 21045835
[TBL] [Abstract][Full Text] [Related]
20. Synergistic combination of gemcitabine and dietary molecule induces apoptosis in pancreatic cancer cells and down regulates PKM2 expression.
Pandita A; Kumar B; Manvati S; Vaishnavi S; Singh SK; Bamezai RN
PLoS One; 2014; 9(9):e107154. PubMed ID: 25197966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
